- Home
- HOTH vs KLTO Comparison
HOTH vs KLTO Comparison
Compare HOTH & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- KLTO
- Stock Information
- Founded
- HOTH 2017
- KLTO 2019
- Country
- HOTH United States
- KLTO United States
- Employees
- HOTH N/A
- KLTO N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- KLTO
- Sector
- HOTH Health Care
- KLTO
- Exchange
- HOTH Nasdaq
- KLTO NYSE
- Market Cap
- HOTH 8.3M
- KLTO 9.8M
- IPO Year
- HOTH 2019
- KLTO N/A
- Fundamental
- Price
- HOTH $0.98
- KLTO $0.20
- Analyst Decision
- HOTH Strong Buy
- KLTO
- Analyst Count
- HOTH 4
- KLTO 0
- Target Price
- HOTH $4.75
- KLTO N/A
- AVG Volume (30 Days)
- HOTH 623.8K
- KLTO 78.7K
- Earning Date
- HOTH 05-13-2025
- KLTO 05-15-2025
- Dividend Yield
- HOTH N/A
- KLTO N/A
- EPS Growth
- HOTH N/A
- KLTO N/A
- EPS
- HOTH N/A
- KLTO N/A
- Revenue
- HOTH N/A
- KLTO N/A
- Revenue This Year
- HOTH N/A
- KLTO N/A
- Revenue Next Year
- HOTH N/A
- KLTO N/A
- P/E Ratio
- HOTH N/A
- KLTO N/A
- Revenue Growth
- HOTH N/A
- KLTO N/A
- 52 Week Low
- HOTH $0.58
- KLTO $0.20
- 52 Week High
- HOTH $3.80
- KLTO $13.10
- Technical
- Relative Strength Index (RSI)
- HOTH 42.23
- KLTO N/A
- Support Level
- HOTH $1.01
- KLTO N/A
- Resistance Level
- HOTH $1.19
- KLTO N/A
- Average True Range (ATR)
- HOTH 0.07
- KLTO 0.00
- MACD
- HOTH -0.01
- KLTO 0.00
- Stochastic Oscillator
- HOTH 23.82
- KLTO 0.00
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.